TC-1827
 | |
| Names | |
|---|---|
| Preferred IUPAC name (2S,4E)-N-Methyl-5-(pyrimidin-5-yl)pent-4-en-2-amine | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
PubChem CID | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C10H15N3 | |
| Molar mass | 177.251 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
TC-1827 is an orally active, selective agonist of the α4β2 nicotinic receptors. Administration of TC-1827 improved memory and learning in a variety of rodents and increased long-term potentiation in hippocampal slices. In addition, the compound was without significant cardiovascular side effects, except for a small, transient rise in arterial blood pressure. The pro-cognitive effects of TC-1827 last much longer than the short half life (0.2 - 1.0 hours) would suggest.[1]
References
[edit]- ^ Bohme, Georg Andrees (May 2004). "In vitro and in vivo characterization of TC-1827, a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity". Drug Development Research. 62 (1): 26–40. doi:10.1002/ddr.10352. S2CID 86072368.